Pilatus Biosciences inks clinical trial collaboration with Roche to evaluate PLT012 in first-in-human study in hepatocellular carcinoma: Epalinges, Switzerland Saturday, August 16 ...

New findings reveal promising efficacy of irpagratinib and atezolizumab in treating advanced hepatocellular carcinoma with ...

Immmunotherapy-based treatments demonstrate effectiveness and safety profiles consistent with clinical trials in real-world setting.

Atezolizumab and bevacizumab enhance TACE effectiveness, significantly extending progression-free survival in unresectable ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Meeting Coverage > GuCS Cabozantinib Plus Atezolizumab Delays Progression in mCRPC — Combination improved PFS versus more hormonal therapy, but control arm questioned by Mike Bassett, Staff ...

Meeting Coverage > WCLC New Data Bolster Atezolizumab as Adjuvant Tx in NSCLC — Overall survival benefit now demonstrated by Leah Lawrence, Contributing Writer, MedPage Today August 9, 2022 ...

Based on the data presented at ASCO 2021, the FDA approved adjuvant atezolizumab in October 2021 for patients with PD-L1–positive resected stages II and IIIA non–small cell lung cancer.

Atezolizumab, a programmed death-ligand 1 (PD-L1) inhibitor, is already approved for the treatment of bladder cancer and small cell lung cancer (SCLC). It is also approved for use in second-line ...

Treatment with atezolizumab resulted in a median overall survival duration of 15.9 months, with an objective response rate of 23%, rising to 28% in patients with the highest levels of PD-L1 ...

Atezolizumab plus bevacizumab appeared well-tolerated and resulted in a 40% objective response rate among patients with malignant peritoneal mesothelioma, according to phase 2 study results ...